Verdiva Bio

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic disorders. Founded in 2024 and headquartered in London, the company acquired global rights (outside Greater China and South Korea) to an industry-leading pipeline from Sciwind Biosciences.

Verdiva's pipeline includes a phase 2-ready, once-weekly oral GLP-1 receptor agonist — a potential first-in-class treatment for obesity — as well as oral and injectable amylin agonists. The company is led by CEO Khurem Farooq, formerly CEO of Aiolos Bio and Gyroscope Therapeutics, alongside an experienced team of drug developers and biotech company builders.

In January 2025, Verdiva launched with an oversubscribed Series A of over $410 million, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures and LYFE Capital.